Recent evidence supports the use of GLP-1 RAs in patients with obesity-related HFpEF
It is thought to reduce melanin production, leading to a more even skin tone
It is worth noting that the pathophysiological adipose tissue microenvironment induces a significantly increased expression of miR-210-3p
Concurrently, an observed surge in growth hormone levels, which typically accompanies muscle resistance, may add complexity to this molecular interplay
Here's what Found's program is built on: - Lower doses of GLP-1s provide metabolic benefits with improved tolerability (Nature, 2025) - 94% reduction in diabetes progression in people with prediabetes (NEJM, 2017) - Improved insulin sensitivity in PCOS (Reproductive Sciences, 2022) - Cardiovascular benefits independent of weight (Annals of Internal Medicine, 2024) - Reduction in systemic inflammation (Cells, 2024) Our approach: Apply these research insights to early intervention, informed also by clinical practice and real-world patient outcomes
Am J Surg Pathol (2019) 43:133140